GRAIL Valuation

Is GRAL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GRAL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate GRAL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate GRAL's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GRAL?

Key metric: As GRAL is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for GRAL. This is calculated by dividing GRAL's market cap by their current revenue.
What is GRAL's PS Ratio?
PS Ratio	4.7x
Sales	US$117.67m
Market Cap	US$550.38m

GRAL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does GRAL's PS Ratio compare to its peers?

The above table shows the PS ratio for GRAL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	15.4x
ARCT Arcturus Therapeutics Holdings	2.9x	35.3%	US$462.4m
YMAB Y-mAbs Therapeutics	5.5x	12.3%	US$452.4m
FHTX Foghorn Therapeutics	17.1x	32.1%	US$429.2m
STOK Stoke Therapeutics	36.2x	50.2%	US$596.9m
GRAL GRAIL	4.7x	17.9%	US$550.4m

Price-To-Sales vs Peers: GRAL is good value based on its Price-To-Sales Ratio (4.7x) compared to the peer average (15.4x).

Price to Sales Ratio vs Industry

How does GRAL's PS Ratio compare vs other companies in the US Biotechs Industry?

129 Companies	Price / Sales	Estimated Growth	Market Cap
GILD Gilead Sciences	4x	2.4%	US$111.86b
BIIB Biogen	2.4x	1.3%	US$23.03b
MRNA Moderna	3.1x	6.8%	US$14.72b
INCY Incyte	3.4x	8.9%	US$13.56b

129 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: GRAL is good value based on its Price-To-Sales Ratio (4.7x) compared to the US Biotechs industry average (9.6x).

Price to Sales Ratio vs Fair Ratio

What is GRAL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GRAL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	4.7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate GRAL's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

5.3%

17.0%

Collegium Pharmaceutical

US$980.7m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$29.96

1.3%

15.1%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$56.91

0.6%

9.8%